MorphoSys Inks Deal With HIBio That Includes Licensing of Two Antibody Candidates

Human Immunology Biosciences (HIBio) has entered into an exclusive licensing deal with MorphoSys for two investigational antibodies for treatment of autoimmune diseases.

Under the agreement, which is potentially worth up to $1 billion for MorphoSys, HIBio will develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody.

Under the agreement, HIBio gains exclusive worldwide rights for felzartamab, with the exception of China, and for MOR210, except for China and South Korea.

The two antibodies are part of HIBio’s strategy of “developing targeted therapies for patients with autoimmune diseases, where unmet need remains high,” said HIBio CEO Travis Murdoch.